Inhibition of Lapatinib-induced Kinome Reprogramming in ERBB2-positive Breast Cancer by Targeting BET Family Bromodomains

Therapeutics such as lapatinib that target ERBB2 often provide initial clinical benefit but resistance frequently develops. Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Rep
Egile Nagusiak: Stuhlmiller, Timothy J., Miller, Samantha M., Zawistowski, Jon S., Nakamura, Kazuhiro, Beltran, Adriana S., Duncan, James S., Angus, Steven P., Collins, Kyla A. L., Granger, Deborah A., Reuther, Rachel A., Graves, Lee M., Gomez, Shawn M., Kuan, Pei-Fen, Parker, Joel S., Chen, Xin, Sciaky, Noah, Carey, Lisa A., Earp, H. Shelton, Jin, Jian, Johnson, Gary L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4408261/
https://ncbi.nlm.nih.gov/pubmed/25865888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2015.03.037
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak